Lithuanian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Stereotactic Laser Ablation for Temporal Lobe Epilepsy

Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Nuoroda įrašoma į mainų sritį
StatusasVerbavimas
Rėmėjai
Medtronic Navigation, Inc.

Raktažodžiai

Santrauka

The study is designed to evaluate the safety and efficacy of the Visualase MRI-guided laser ablation system for mesial temporal epilepsy (MTLE).

apibūdinimas

The purpose of the study is to evaluate the safety and efficacy of the Visualase MRI-guided laser ablation system for necrotization or coagulation of epileptogenic foci in patients with intractable mesial temporal lobe epilepsy.

The study will include approximately 150 adult patients with drug-resistant MTLE treated at selected epilepsy centers across the United States. After the Visualase procedure, patients will be followed for 12 months and evaluated for freedom from seizures, quality of life, adverse events, and neuropsychological outcomes.

Datos

Paskutinį kartą patikrinta: 10/31/2019
Pirmasis pateikimas: 07/14/2016
Numatytas registravimas pateiktas: 07/20/2016
Pirmas paskelbtas: 07/25/2016
Paskutinis atnaujinimas pateiktas: 11/19/2019
Paskutinis atnaujinimas paskelbtas: 11/21/2019
Faktinė studijų pradžios data: 11/30/2016
Numatoma pirminio užbaigimo data: 04/30/2022
Numatoma studijų užbaigimo data: 04/30/2022

Būklė ar liga

Temporal Lobe Epilepsy

Intervencija / gydymas

Device: Treatment

Fazė

-

Rankų grupės

RankaIntervencija / gydymas
Experimental: Treatment
Visualase MRI-guided laser ablation procedure
Device: Treatment
All subjects will undergo MRI-guided laser ablation of the amygdala and hippocampus with the Visualase System.

Tinkamumo kriterijai

Amžius, tinkami studijuoti 18 Years Į 18 Years
Tinkamos studijoms lytysAll
Priima sveikus savanoriusTaip
Kriterijai

Inclusion Criteria:

- History of drug-resistant mesial temporal lobe epilepsy (MTLE)

- If the subject has a vagus nerve stimulator (VNS), must have failed to achieve sustained seizure freedom with the VNS implanted for at least 6 months

- On stable antiepileptic drugs (AEDs) (and/or stable VNS setting, if applicable) and compliant with medication use

- An average of at least 1 complex partial or secondarily generalized seizure compatible with MTLE per month

- Seizure symptoms and/or auras compatible with MTLE

- Video EEG shows evidence of seizures from one temporal lobe consistent with MTLE

- MRI has evidence consistent with mesial temporal lobe sclerosis

- Willing and able to remain on stable AEDs (and stable VNS setting, if applicable) for 12 months following the Visualase procedure

- Willing and able to comply with protocol requirements

- Able to complete study assessments in English or Spanish language

Exclusion Criteria:

- Unwilling or unable to sign the study informed consent form

- Pregnant or intends to become pregnant during the course of the study

- Currently implanted with a device contraindicating MRI

- Progressive brain lesions and/or tumors not associated with epileptic disease state

- History of previous intracranial surgery for treatment of epileptic seizures

- Persistent extra-temporal or predominant contralateral focal interictal spikes or slowing, or generalized interictal spikes on EEG

- Seizures with contralateral or extra-temporal ictal onset on EEG

- Aura and/or ictal behavior suggest an extra-temporal focus

- MRI evidence of epileptogenic, extra-temporal lesions, dual pathology in the temporal lobe, or contralateral hippocampal MRI increased signal and/or loss of architecture

- If additional testing has been performed, results are discordant with the seizure focus scheduled for ablation

- Non-compliance with AED requirements

- IQ < 70

- Dementia or other progressive neurological disease

- Unstable major psychiatric illness, psychogenic non-epileptic seizures, or medical illness that would contraindicate the Visualase procedure or affect the neuropsychological assessments

- Participation in other research that may potentially interfere with SLATE endpoint(s)

- Allergy to gadolinium

Rezultatas

Pirminės rezultatų priemonės

1. Incidence of qualifying adverse events [12 months]

2. Seizure freedom, defined as Engel Classification of Postoperative Outcome Class I [12 months]

Antrinės rezultatų priemonės

1. Seizure freedom compared to historical controls [12 months]

2. Seizure freedom, including subjects retreated with Visualase [12 months]

3. Change in Boston Naming Test scores [Baseline and 12 months]

4. Change in Rey Auditory Verbal Learning Test scores [Baseline and 12 months]

5. Change in Short Form-36 (SF-36) Health Survey scores [Baseline and 12 months]

6. Change in Quality of Life in Epilepsy (QOLIE-31) scores [Baseline and 12 months]

Prisijunkite prie mūsų
„Facebook“ puslapio

Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu

  • Dirba 55 kalbomis
  • Žolelių gydymas, paremtas mokslu
  • Vaistažolių atpažinimas pagal vaizdą
  • Interaktyvus GPS žemėlapis - pažymėkite vaistažoles vietoje (netrukus)
  • Skaitykite mokslines publikacijas, susijusias su jūsų paieška
  • Ieškokite vaistinių žolelių pagal jų poveikį
  • Susitvarkykite savo interesus ir sekite naujienas, klinikinius tyrimus ir patentus

Įveskite simptomą ar ligą ir perskaitykite apie žoleles, kurios gali padėti, įveskite žolę ir pamatykite ligas bei simptomus, nuo kurių ji naudojama.
* Visa informacija pagrįsta paskelbtais moksliniais tyrimais

Google Play badgeApp Store badge